Abstract 2342P
Background
Single tumor cells (STCs) are a manifestation of intratumor morphological heterogeneity and most likely arise from multicellular tumor structures as a result of cancer invasion. In recent years, the appearance of STCs has been described as tumor budding in the invasive front. However, there are no clear data on the clinical significance of these cells in breast cancer patients.
Methods
The study included 230 patients diagnosed with invasive breast carcinoma of the nonspecific type, luminal molecular subtypes. H&E staining was used to detect STCs in breast tissue. STCs (or detached individual tumor cells) were detected in the entire tumor tissue in contrast to tumor buds located in the invasive front, and were defined as tumor cells located outside multicellular tumor structures but similar to them in cytological features. 7-color immunofluorescence analysis was used to study the population composition of the microenvironment (ME) of STCs. Laser microdissection of STCs ME and sequencing on NextSeq500 (Illumina, USA) was performed.
Results
Patients who had a STCs had a 5.8-fold increased risk (CI95% 2.4-14.1) of developing distant metastases compared to patients who did not have a STCs (p=0.0001). Patients who had no STCs had a better metastatic-free survival (91.8%) than patients who had a STCs (49.1) (p<0.0001). The relative risk of distant metastases in breast cancer patients where only Th2-like immune reaction is found in the ME is 2.37 (CI95% 1.25-4.42) times higher than in patients where only Th1-like immune reaction (p=0.0352). In addition, a Top 10 analysis of up- and downregulated genes in the STCs ME in breast cancer patients depending on the status of distant metastasis was performed. Decrease of CD52 (7-fold), NUDT3 (6-fold), TAP1 (6-fold) (p<0.001) genes expression and increase of LAMA5 (4-fold), LPCAT1 (5-fold), FLVCR1 (5-fold) (p<0.001) genes expression were detected in the STCs ME of breast cancer patients with distant metastases compared to those without.
Conclusions
A novel simple prognostic criterion for predicting breast cancer metastasis has been developed. The microenvironment has been shown to play an important role in the metastatic potential of a single tumour cells. Immunosignatures of the pro-tumour microenvironment have been identified.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Tomsk National Research Medical Center.
Funding
The study was supported by the Russian Science Foundation (grant #23-15-00135).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2325P - Selinexor (XPO1 inhibitor) in combination with tepotinib (MET inhibitor) potentially inhibits SHOC2 and KRAS G12C in KRAS G12C mutant non-small cell lung cancer
Presenter: Rafael Rosell
Session: Poster session 16
2326P - Circulating tumor DNA (ctDNA) dynamics and clinical outcome in metastatic colorectal cancer (mCRC) patients (pts) undergoing front-line chemotherapy
Presenter: Michele Ghidini
Session: Poster session 16
2327P - The impact of the microenvironment on the intratumoral cellular heterogeneity in colorectal cancer
Presenter: Idan Carmi
Session: Poster session 16
2328P - Alternative molecular mechanisms underpinning breast invasive lobular carcinoma identified by genomics-driven artificial intelligence model
Presenter: Fresia Pareja
Session: Poster session 16
2329P - Evidence for the utility of artificial intelligence and image analysis in Ki-67 quantification in solid tumors
Presenter: Xavier Pichon
Session: Poster session 16
2331P - Interest of next generation sequencing (NGS) for integrated molecular diagnosis of HER2-low breast cancer
Presenter: Jean Louis Merlin
Session: Poster session 16
2332P - Overall survival in breast cancer patients with HER2-low status single- center experience
Presenter: Joanna Huszno
Session: Poster session 16
2333P - Associating BRCA1 hypermethylation with clinicopathological and molecular variables in triple-negative breast cancers
Presenter: Anna Karlsson
Session: Poster session 16
2334P - Pathologic patterns following different neoadjuvant therapies in non-small cell lung cancer (NSCLC)
Presenter: Annikka Weissferdt
Session: Poster session 16